Editas Medicine Stock Price, News & Analysis (NASDAQ:EDIT)

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 1 sell rating, 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" EDIT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares.
View EDIT analyst ratings or view top-rated stocks.

12 brokerages have issued 1-year price targets for Editas Medicine's stock. Their EDIT share price targets range from $7.00 to $30.00. On average, they expect the company's share price to reach $13.92 in the next year. This suggests a possible upside of 29.2% from the stock's current price.
View analysts price targets for EDIT or view top-rated stocks among Wall Street analysts.

Editas Medicine's stock was trading at $8.87 on January 1st, 2023. Since then, EDIT shares have increased by 21.4% and is now trading at $10.77.
View the best growth stocks for 2023 here.

Editas Medicine saw a decrease in short interest in November. As of November 15th, there was short interest totaling 15,870,000 shares, a decrease of 5.4% from the October 31st total of 16,770,000 shares. Based on an average daily trading volume, of 1,630,000 shares, the short-interest ratio is currently 9.7 days.
View Editas Medicine's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our EDIT earnings forecast.

Editas Medicine, Inc. (NASDAQ:EDIT) announced its quarterly earnings data on Friday, November, 3rd. The company reported ($0.55) EPS for the quarter, beating analysts' consensus estimates of ($0.64) by $0.09. The firm earned $5.34 million during the quarter, compared to analyst estimates of $3.70 million. Editas Medicine had a negative net margin of 792.70% and a negative trailing twelve-month return on equity of 54.24%. The company's revenue for the quarter was up 1171.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.81) earnings per share.

ETFs with the largest weight of Editas Medicine (NASDAQ:EDIT) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), iShares Genomics Immunology and Healthcare ETF (IDNA), Horizon Kinetics Medical ETF (MEDX), Direxion Moonshot Innovators ETF (MOON), Global X Genomics & Biotechnology ETF (GNOM) and AXS Green Alpha ETF (NXTE).WisdomTree BioRevolution Fund (WDNA) and

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Block (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS).

(EDIT) raised $100 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

Editas Medicine's stock is owned by many different retail and institutional investors. Top institutional shareholders include Northern Trust Corp (1.09%), Charles Schwab Investment Management Inc. (0.84%), Rafferty Asset Management LLC (0.69%), Mirae Asset Global Investments Co. Ltd. (0.46%), Bank of New York Mellon Corp (0.38%) and Barclays PLC (0.34%). Insiders that own company stock include Baisong Mei, Bruce Eaton, Charles Albright, Gilmore Neil O'neill, James C Mullen, Lisa Anne Michaels, Mark S Shearman and Michelle Robertson.
View institutional ownership trends.

Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.